Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | NADP dependent isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.2038 |
Brugia malayi | Smad1 | 0.001 | 0.0316 | 0.0316 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0019 | 0.0984 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.359 | 1 |
Echinococcus multilocularis | isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.2038 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.359 | 1 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.2038 |
Echinococcus multilocularis | isocitrate dehydrogenase 2 (NADP+) | 0.0019 | 0.0984 | 0.2038 |
Loa Loa (eye worm) | Smad1 | 0.001 | 0.0316 | 0.0316 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.274 | 0.7404 |
Brugia malayi | MH1 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.359 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.359 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.359 | 1 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0.0984 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.359 | 0.359 |
Brugia malayi | MH2 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0019 | 0.0984 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.274 | 0.7404 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.274 | 0.5 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0019 | 0.0984 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.274 | 0.7404 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0.0984 | 0.5 |
Loa Loa (eye worm) | MH1 domain-containing protein | 0.001 | 0.0316 | 0.0316 |
Brugia malayi | isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.0984 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.274 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.359 | 1 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0019 | 0.0984 | 0.5 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.2038 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.274 | 0.7404 |
Loa Loa (eye worm) | isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.0984 |
Brugia malayi | MH2 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0.0984 | 0.5 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.2038 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.001 | 0.0316 | 0.0316 |
Brugia malayi | Isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.0984 |
Brugia malayi | MH1 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.274 | 0.5 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0019 | 0.0984 | 0.5 |
Brugia malayi | hypothetical protein | 0.0043 | 0.274 | 0.274 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.274 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.359 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.359 | 0.359 |
Schistosoma mansoni | NADP-specific isocitrate dehydrogenase | 0.0019 | 0.0984 | 0.2038 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1458 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.8913 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 10.3225 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.